Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Revive Therapeutics Ltd (RVVTF)

Revive Therapeutics Ltd (RVVTF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0051 +25.49%
on 03/03/25
0.0096 -33.33%
on 02/19/25
-0.0008 (-11.11%)
since 02/14/25
3-Month
0.0050 +28.00%
on 01/29/25
0.0096 -33.33%
on 02/19/25
-0.0002 (-3.03%)
since 12/13/24
52-Week
0.0050 +28.00%
on 01/29/25
0.0269 -76.21%
on 03/18/24
-0.0136 (-68.00%)
since 03/14/24

Most Recent Stories

More News
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program

RVV.CN : 0.0050 (unch)
RVVTF : 0.0064 (+3.23%)
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

RVV.CN : 0.0050 (unch)
RVVTF : 0.0064 (+3.23%)
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

RVV.CN : 0.0050 (unch)
RVVTF : 0.0064 (+3.23%)
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

RVV.CN : 0.0050 (unch)
RVVTF : 0.0064 (+3.23%)
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

RVV.CN : 0.0050 (unch)
RVVTF : 0.0064 (+3.23%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty...

RVVTF : 0.0064 (+3.23%)
RVV.CN : 0.0050 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0064 (+3.23%)
RVV.CN : 0.0050 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company submits Data Access Plan to the FDA to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0064 (+3.23%)
RVV.CN : 0.0050 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26,...

RVVTF : 0.0064 (+3.23%)
RVV.CN : 0.0050 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company submitted request to the FDA to determine potential new clinical endpoints for FDA consideration for EUA...

RVVTF : 0.0064 (+3.23%)
RVV.CN : 0.0050 (unch)

Key Turning Points

3rd Resistance Point 0.0075
2nd Resistance Point 0.0072
1st Resistance Point 0.0068
Last Price 0.0064
1st Support Level 0.0061
2nd Support Level 0.0058
3rd Support Level 0.0054

See More

52-Week High 0.0269
Fibonacci 61.8% 0.0185
Fibonacci 50% 0.0159
Fibonacci 38.2% 0.0134
Last Price 0.0064
52-Week Low 0.0050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar